Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

10x Genomics (TXG) Operating Expenses (2018 - 2026)

10x Genomics' Operating Expenses history spans 8 years, with the latest figure at $132.6 million for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 17.54% to $132.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $504.9 million, a 17.1% decrease, with the full-year FY2025 number at $504.9 million, down 17.1% from a year prior.
  • Operating Expenses hit $132.6 million in Q4 2025 for 10x Genomics, roughly flat from $132.5 million in the prior quarter.
  • Over the last five years, Operating Expenses for TXG hit a ceiling of $190.3 million in Q3 2023 and a floor of $95.0 million in Q2 2025.
  • Historically, Operating Expenses has averaged $141.1 million across 5 years, with a median of $143.6 million in 2022.
  • The widest YoY moves for Operating Expenses: up 67.77% in 2021, down 73.8% in 2021.
  • Tracing TXG's Operating Expenses over 5 years: stood at $131.8 million in 2021, then rose by 8.15% to $142.5 million in 2022, then increased by 19.98% to $171.0 million in 2023, then fell by 5.95% to $160.8 million in 2024, then decreased by 17.54% to $132.6 million in 2025.
  • Business Quant data shows Operating Expenses for TXG at $132.6 million in Q4 2025, $132.5 million in Q3 2025, and $95.0 million in Q2 2025.